Navigation Links
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Date:12/2/2009

inical trials for KRX-0401; the risk that the data (both safety and efficacy) from the Phase 3 trial will not coincide with the data analyses from the Phase 1 / 2 clinical trial previously reported by the Company; the risk that fast track designation and priority review may not result in earlier approval; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.


KERYX CONTACT:
Lauren Fischer
Director, Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5962
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
2. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
7. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
8. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015  Depomed, Inc. (NASDAQ: DEPO ) ("Depomed" ... of Directors, after careful consideration and with the ... has unanimously rejected the purported revised, highly conditional, ... (NASDAQ: HZNP ) ("Horizon") to acquire all ... all-stock transaction (the "July 21 Proposal"). ...
(Date:7/29/2015)... Alvarado Hospital unveiled its new facility ... & Joint Institute. The institute is entirely devoted ... surgery and joint replacement. The Spine & Joint ... experience-focused approach. For example, patients are encouraged to ... than patient gowns. "From the ...
(Date:7/29/2015)... , July 29, 2015  Cryoport, Inc. ... "Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, announced today that ... common stock and warrants (the "Units") under a registered ...
Breaking Medicine Technology:Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 3Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 4Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 5Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 6Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 7Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 8Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 9The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3
... in US, Finds Allergy Immunotherapy ... Beneficial Even When Treatment Not Completed, MOSS BEACH, ... economics and outcomes research, today announced,findings of a landmark ... to children and significantly reduces health,care costs, even when ...
... Ala., Jan. 23 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... on activities,conducted following release of the preliminary ... development plan for intramuscular (i.m.) peramivir., ... release of preliminary Phase II results in ...
Cached Medicine Technology:Study Says Allergy Shots Help Children, Reduce Health Care Costs 2Study Says Allergy Shots Help Children, Reduce Health Care Costs 3BioCryst Updates Peramivir Clinical Development Plan 2BioCryst Updates Peramivir Clinical Development Plan 3BioCryst Updates Peramivir Clinical Development Plan 4BioCryst Updates Peramivir Clinical Development Plan 5BioCryst Updates Peramivir Clinical Development Plan 6
(Date:7/29/2015)... New Port Richey, FL (PRWEB) , ... July ... ... across the nation have become increasingly aware of the impact drinking and substance ... morale, and increased illness. Financial loss is tagged in the billions per year. ...
(Date:7/29/2015)... ... , ... " Core Organizer ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... help anyone get organized. , Wouldn’t it be great if everyone could be a ...
(Date:7/29/2015)... ... 29, 2015 , ... More than 28,000 students in Pennsylvania ... living with autism will converge upon Penn State to share the latest updates ... Autism Conference will be held Aug. 3-6 at the Penn Stater Conference Center ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to The Spirits Business ... is directly responsible for stimulating and perpetuating alcohol use disorders. Humans have the same ... of the National academy of Sciences, and has given researchers inklings to explore Rsu1 ...
(Date:7/29/2015)... ... 29, 2015 , ... With a new community program in ... Cancer Support Services and announced a new charity campaign to raise funds to ... groups, workshops and educational programs at no charge. Scott Campbell Agency initiates ...
Breaking Medicine News(10 mins):Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 2Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 3Health News:Get More Organized with the Core Organizer App 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 2Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 3
... Statement of Michael Bender, Plaintiff, WASHINGTON, June 5 ... Administration has finally agreed to comply with the law,and ... substance that poses a,health risk to pregnant women and ... this week, our lawsuit, Moms,Against Mercury et al. v. ...
... four-week and seventeen-week periods ended May 29,2008., ... Periods ended May 29, 2008 ... Month Year to Date (Dollars in millions) ... weeks), Total retail drug store sales ...
... Medical Corp.,(Nasdaq Capital Market: ESMC) announced today that ... Scientific, Inc. ("Drew") acquired JAS,Diagnostics, Inc. ("JAS"). JAS ... in vitro diagnostics ("IVD") reagents that markets its ... the,world. JAS, based in Miami, Florida, generates annual ...
... Health Magazine, SEATTLE, June 5 Kagome, one ... Mango Orchard natural 100 percent juice,blend have been named ... With the help of top health experts, Health ... fitness to the ultimate test,and unveiled a total of ...
... a lower cost tool than MRI for evaluating new ... News) -- Researchers say they can cheaply and easily ... off a tumor,s blood supply by using the same ... a technique called bioluminescence imaging (BLI), the University of ...
... Massachusetts School of,Professional Psychology, WEST ROXBURY, Mass., ... about the ,invisible wounds of war, - the ... and post traumatic,stress disorder (PTSD) - which raise ... suicide. We need to begin focusing on their,recuperation ...
Cached Medicine News:Health News:US FDA Admits Risks of Mercury Dental Fillings, Settles Lawsuit 2Health News:Longs Reports Preliminary May Retail Drug Store Sales 2Health News:Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics 2Health News:Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics 3Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 2Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 3Health News:Tracking Cancer Drug's Effectiveness 2Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2
Anti-Tg and Anti-TPO are two major autoantibodies implicated in autoimmune related thyroiditis and aid in the differential diagnosis of Hashimoto's thyroiditis and Graves' disease....
... is an automated, turbidimetric, whole- blood assay ... the ability of activated platelets to bind ... of the VerifyNow IIb/IIIa assay device contains ... this analysis. Within the well is an ...
... The Company's first commercial product is ... with single-use, disposable assay devices . The ... products are direct use of a vacuum-type ... a result in minutes. VerifyNow IIb/IIIa, the ...
... ComboMap system provides both pressure and ... singly or in a combined screen ... SmartWire and Volcano's unique Doppler FloWire. ... valuable tools to assess ambiguous or ...
Medicine Products: